Nicole R Tartaglia1, Natalie Ayari, Christa Hutaff-Lee, Richard Boada. 1. Neurodevelopmental and Behavioral Pediatrics, Department of Pediatrics, University of Colorado School of Medicine, Children's Hospital Colorado, 13123 East 16th Avenue, Aurora, CO, USA. Nicole.tartaglia@childrenscolorado.org
Abstract
OBJECTIVE: Attentional problems, hyperactivity, and impulsivity have been described as behavioral features associated with sex chromosome aneuploidy (SCA). In this study, the authors compare attention-deficit hyperactivity disorder (ADHD) symptoms in 167 participants aged 6 to 20 years with 4 types of SCA (XXY n = 56, XYY n = 33, XXX n = 25, and XXYY n = 53). They also evaluate factors associated with ADHD symptomatology (cognitive and adaptive scores, prenatal vs postnatal ascertainment) and describe the clinical response to psychopharmacologic medications in a subset of patients treated for ADHD. METHODS: Evaluation included medical and developmental history, cognitive and adaptive functioning assessment, and parent and teacher ADHD questionnaires containing DSM-IV criteria. RESULTS: In the total study group, 58% (96/167) met DSM-IV criteria for ADHD on parent-report questionnaires (36% in XXY, 52% in XXX, 76% in XYY, and 72% in XXYY). The Inattentive subtype was most common in XXY and XXX, whereas the XYY and XXYY groups were more likely to also have hyperactive/impulsive symptoms. There were no significant differences in Verbal, Performance, or Full Scale IQ between children with symptom scores in the ADHD range compared with those below the ADHD range. However, adaptive functioning scores were significantly lower in the group whose scores in the ADHD range were compared with those of the group who did not meet ADHD DSM-IV criteria. Those with a prenatal diagnosis of XXY were less likely to meet criteria for ADHD compared with the postnatally diagnosed group. Psychopharmacologic treatment with stimulants was effective in 78.6% (66/84). CONCLUSIONS: Children and adolescents with SCA are at increased risk for ADHD symptoms. Recommendations for ADHD evaluation and treatment in consideration of other aspects of the SCA medical and behavioral phenotype are provided.
OBJECTIVE: Attentional problems, hyperactivity, and impulsivity have been described as behavioral features associated with sex chromosome aneuploidy (SCA). In this study, the authors compare attention-deficit hyperactivity disorder (ADHD) symptoms in 167 participants aged 6 to 20 years with 4 types of SCA (XXY n = 56, XYY n = 33, XXX n = 25, and XXYY n = 53). They also evaluate factors associated with ADHD symptomatology (cognitive and adaptive scores, prenatal vs postnatal ascertainment) and describe the clinical response to psychopharmacologic medications in a subset of patients treated for ADHD. METHODS: Evaluation included medical and developmental history, cognitive and adaptive functioning assessment, and parent and teacher ADHD questionnaires containing DSM-IV criteria. RESULTS: In the total study group, 58% (96/167) met DSM-IV criteria for ADHD on parent-report questionnaires (36% in XXY, 52% in XXX, 76% in XYY, and 72% in XXYY). The Inattentive subtype was most common in XXY and XXX, whereas the XYY and XXYY groups were more likely to also have hyperactive/impulsive symptoms. There were no significant differences in Verbal, Performance, or Full Scale IQ between children with symptom scores in the ADHD range compared with those below the ADHD range. However, adaptive functioning scores were significantly lower in the group whose scores in the ADHD range were compared with those of the group who did not meet ADHD DSM-IV criteria. Those with a prenatal diagnosis of XXY were less likely to meet criteria for ADHD compared with the postnatally diagnosed group. Psychopharmacologic treatment with stimulants was effective in 78.6% (66/84). CONCLUSIONS:Children and adolescents with SCA are at increased risk for ADHD symptoms. Recommendations for ADHD evaluation and treatment in consideration of other aspects of the SCA medical and behavioral phenotype are provided.
Authors: Mark Wolraich; Lawrence Brown; Ronald T Brown; George DuPaul; Marian Earls; Heidi M Feldman; Theodore G Ganiats; Beth Kaplanek; Bruce Meyer; James Perrin; Karen Pierce; Michael Reiff; Martin T Stein; Susanna Visser Journal: Pediatrics Date: 2011-10-16 Impact factor: 7.124
Authors: Nancy Raitano Lee; Gregory L Wallace; Liv S Clasen; Rhoshel K Lenroot; Jonathan D Blumenthal; Samantha L White; Mark J Celano; Jay N Giedd Journal: J Int Neuropsychol Soc Date: 2011-05 Impact factor: 2.892
Authors: Christina L Fales; Barbara J Knowlton; Keith J Holyoak; Daniel H Geschwind; Ronald S Swerdloff; Irene Gaw Gonzalo Journal: J Int Neuropsychol Soc Date: 2003-09 Impact factor: 2.892
Authors: Victoria Leggett; Patricia Jacobs; Kate Nation; Gaia Scerif; Dorothy V M Bishop Journal: Dev Med Child Neurol Date: 2010-01-05 Impact factor: 5.449
Authors: Judith L Ross; Luke Bloy; Timothy P L Roberts; Judith Miller; Chao Xing; Lawrence A Silverman; Andrew R Zinn Journal: Am J Med Genet B Neuropsychiatr Genet Date: 2019-06-03 Impact factor: 3.568
Authors: Kristen Wigby; Cheryl D'Epagnier; Susan Howell; Amy Reicks; Rebecca Wilson; Lisa Cordeiro; Nicole Tartaglia Journal: Am J Med Genet A Date: 2016-09-19 Impact factor: 2.802
Authors: Talia Thompson; Susan Howell; Shanlee Davis; Rebecca Wilson; Jennifer Janusz; Richard Boada; Laura Pyle; Nicole Tartaglia Journal: Am J Med Genet C Semin Med Genet Date: 2020-05-25 Impact factor: 3.908
Authors: Nicole Tartaglia; Susan Howell; Shanlee Davis; Karen Kowal; Tanea Tanda; Mariah Brown; Cristina Boada; Amanda Alston; Leah Crawford; Talia Thompson; Sophie van Rijn; Rebecca Wilson; Jennifer Janusz; Judith Ross Journal: Am J Med Genet C Semin Med Genet Date: 2020-06-07 Impact factor: 3.908
Authors: David S Hong; Fumiko Hoeft; Matthew J Marzelli; Jean-Francois Lepage; David Roeltgen; Judith Ross; Allan L Reiss Journal: J Neurosci Date: 2014-03-05 Impact factor: 6.167